BIOFRONTERA INC (BFRI)
US09077D2099 - Common Stock
Taking everything into account, BFRI scores 2 out of 10 in our fundamental rating. BFRI was compared to 198 industry peers in the Pharmaceuticals industry. BFRI has a bad profitability rating. Also its financial health evaluation is rather negative. BFRI shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
In the past year BFRI has reported negative net income.
In the past year BFRI has reported a negative cash flow from operations.
BFRI had negative earnings in each of the past 5 years.
In the past 5 years BFRI always reported negative operating cash flow.
1.2 Ratios
The Return On Assets of BFRI (-72.08%) is worse than 69.74% of its industry peers.
Looking at the Return On Equity, with a value of -420.07%, BFRI is doing worse than 81.03% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -72.08% | ||
| ROE | -420.07% | ||
| ROIC | N/A |
ROA(3y)-48.06%
ROA(5y)-45.58%
ROE(3y)-251.74%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a decent Gross Margin value of 48.83%, BFRI is doing good in the industry, outperforming 60.51% of the companies in the same industry.
In the last couple of years the Gross Margin of BFRI has declined.
The Profit Margin and Operating Margin are not available for BFRI so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 48.83% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.02%
GM growth 5YN/A
2. Health
2.1 Basic Checks
BFRI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BFRI has been increased compared to 1 year ago.
Compared to 1 year ago, BFRI has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -5.86, we must say that BFRI is in the distress zone and has some risk of bankruptcy.
BFRI has a worse Altman-Z score (-5.86) than 64.62% of its industry peers.
BFRI has a Debt/Equity ratio of 0.81. This is a neutral value indicating BFRI is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.81, BFRI is doing worse than 69.74% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.81 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -5.86 |
ROIC/WACCN/A
WACC8.51%
2.3 Liquidity
BFRI has a Current Ratio of 1.28. This is a normal value and indicates that BFRI is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.28, BFRI is doing worse than 81.03% of the companies in the same industry.
BFRI has a Quick Ratio of 1.28. This is a bad value and indicates that BFRI is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.67, BFRI is doing worse than 87.69% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.28 | ||
| Quick Ratio | 0.67 |
3. Growth
3.1 Past
BFRI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -100.73%.
Looking at the last year, BFRI shows a quite strong growth in Revenue. The Revenue has grown by 18.86% in the last year.
Measured over the past years, BFRI shows a very strong growth in Revenue. The Revenue has been growing by 21.81% on average per year.
EPS 1Y (TTM)-100.73%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q35.71%
Revenue 1Y (TTM)18.86%
Revenue growth 3Y21.81%
Revenue growth 5YN/A
Revenue growth Q2Q4.5%
3.2 Future
Based on estimates for the next years, BFRI will show a very strong growth in Earnings Per Share. The EPS will grow by 26.90% on average per year.
The Revenue is expected to grow by 27.18% on average over the next years. This is a very strong growth
EPS Next Y82.82%
EPS Next 2Y40.4%
EPS Next 3Y26.9%
EPS Next 5YN/A
Revenue Next Year16.25%
Revenue Next 2Y19.43%
Revenue Next 3Y23.09%
Revenue Next 5Y27.18%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
BFRI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BFRI. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as BFRI's earnings are expected to grow with 26.90% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.4%
EPS Next 3Y26.9%
5. Dividend
5.1 Amount
BFRI does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BIOFRONTERA INC
NASDAQ:BFRI (4/26/2024, 7:00:00 PM)
After market: 1.59 0 (0%)1.59
-0.1 (-5.92%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap8.09M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -72.08% | ||
| ROE | -420.07% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 48.83% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover1.22
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.81 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.28 | ||
| Quick Ratio | 0.67 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-100.73%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y82.82%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)18.86%
Revenue growth 3Y21.81%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y